N-diethyl-ethane-1,2-diamine | 100868-65-3

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: N-diethyl-ethane-1,2-diamine
• 英文别名: (1-Aminobutan-2-YL)(ethyl)amine；2-N-ethylbutane-1,2-diamine
• CAS: 100868-65-3
• 化学式: C₆H₁₆N₂
• 分子量: 116.206
• InChiKey: TZGWVMCBTLZVCS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  8
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  38
• 氢给体数：
  2
• 氢受体数：
  2

文献信息

• [EN] NITROGEN-CONTAINING HETEROCYCLIC COMPOUND<br/>[FR] COMPOSÉ HÉTÉROCYCLIQUE CONTENANT DE L'AZOTE
  申请人：TAKEDA PHARMACEUTICAL

  公开号：WO2013018929A1

  公开（公告）日：2013-02-07

  The present invention provides a novel compound having a superior activity as an ERR-α modulator and useful as an agent for the prophylaxis or treatment of ERR-α associated diseases. The present invention relates to a compound represented by the formula (1) wherein each symbol is as defined in the specification, or a salt thereof.

  本发明提供了一种新型的化合物，作为一种ERR-α调节剂具有优越的活性，并可作为预防或治疗与ERR-α相关疾病的药物。本发明涉及一种由公式(1)表示的化合物，其中每个符号如说明书中所定义，或其盐。
• [EN] QUINOLONE DERIVATIVES AS FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITORS<br/>[FR] DÉRIVÉS DE QUINOLONE UTILISÉS EN TANT QU'INHIBITEURS DU RÉCEPTEUR DU FACTEUR DE CROISSANCE DES FIBROBLASTES
  申请人：PRINCIPIA BIOPHARMA INC

  公开号：WO2015120049A1

  公开（公告）日：2015-08-13

  Compounds that are Fibroblast Growth Factor Inhibitors (FGFR) and are therefore useful for the treatment of diseases treatable by inhibition of FGFR are disclosed. Also disclosed are pharmaceutical compositions containing such compounds and processes for preparing such compounds.

  公开了作为成纤维细胞生长因子抑制剂（FGFR）的化合物，因此可用于治疗可以通过抑制FGFR治疗的疾病。还公开了含有此类化合物的药物组合物以及制备此类化合物的过程。
• 2-phenyl benzimidazole derivatives as MCP-1 antagonists
  申请人：Warner-Lambert Company

  公开号：US20020099054A1

  公开（公告）日：2002-07-25

  Benzimidazole derivatives of Formula I or a pharmaceutically acceptable salt thereof are MCP-1 antagonists and are thus useful in the treatment of inflammation, atherosclerosis, restenosis, and immune disorders such as arthritis and transplant rejection 1 wherein A is N or CH; where W, X, Y, and Z can be independently C—R 2 , C—R 3 , C—R 4 , C—R 5 , or N; no more than two of W, X, Y, and Z can be N in any one structure, R 2 , R 3 , R 4 , and R 5 can be independently H, C 1-20 alkyl, halogen, nitro, —SO 2 NR 8 R 9 , alkoxy of from 1-4 carbon atoms; —S(O) p R where p is an integer from 0 to 2; —(CH 2 ) m OR, —(CH 2 ) m COOR, —(CH 2 ) m NR 8 R 9 , —(CH 2 ) m CONR 8 R 9 , —(CH 2 ) m COR, or —CF 3 ; m is an integer of from 0 to 4, R is hydrogen, lower alkyl of from 1-4 carbon atoms, aryl of from 6-10 carbon atoms, or benzyl; R 1 can be H, lower alkyl of from 1-4 carbon atoms, or —(CH 2 ) m —Ph; R 6 is alkyl of from 1-6 carbon atoms or R 7 ; R 7 is (CH 2 ) n NR 10 R 11 ; n is an integer from 2 to 6; R 8 and R 9 can be independently hydrogen, lower alkyl of from 1-4 carbon atoms, or can be taken together to form a ring of from 3-8 atoms having up to one additional heteroatom as O, S, SO 2 , or N—R 12 ; R 10 and R 11 can independently be lower alkyl, —(CH 2 ) m Ph, unsubstituted or substituted with up to three R 2 substituents, or R 10 and R 11 can be taken together to form a ring of from 3-8 atoms which may contain oxygen or NR 12 ; R 12 is hydrogen, lower alkyl, —(CH 2 ) t Ph, where Ph is phenyl unsubstituted or substituted with up to three R 2 substituents; t is an integer of from 0 to 2; or a pharmaceutically acceptable salt thereof.

  公式I中的苯并咪唑衍生物或其药学上可接受的盐是MCP-1拮抗剂，因此在治疗炎症、动脉粥样硬化、再狭窄和免疫紊乱，例如关节炎和移植排斥方面有用。其中A为N或CH；W、X、Y和Z可以独立地为C—R2、C—R3、C—R4、C—R5或N；在任何一个结构中，W、X、Y和Z中不超过两个可以为N；R2、R3、R4和R5可以独立地为H、C1-20烷基、卤素、硝基、—SO2NR8R9、1-4碳原子的烷氧基、—S（O）pR，其中p是0到2的整数、—（CH2）mOR、—（ ）MCOOR、—（ ）mNR8R9、—（ ）MCONR8R9、—（ ）MCOR或—CF3；m是0到4的整数；R是氢、1-4碳原子的低烷基、6-10碳原子的芳基或苄基；R1可以是H、1-4碳原子的低烷基或—（ ）m—Ph；R6是1-6碳原子的烷基或R7；R7是（ ）nNR10R11；n是2到6的整数；R8和R9可以独立地为氢、1-4碳原子的低烷基，或可以一起取代为3-8个原子的环，其中最多有一个额外的杂原子，例如O、S、SO2或N—R12；R10和R11可以独立地为低烷基、未取代或取代了最多三个R2取代基的—（ ）mPh，或R10和R11可以一起形成3-8个原子的环，其中可能含有氧或NR12；R12是氢、低烷基、—（ ）tPh，其中Ph是未取代或取代了最多三个R2取代基的苯基；t是0到2的整数；或其药学上可接受的盐。
• 4-Amino-quinazolines
  申请人：Mederski Werner

  公开号：US20060019974A1

  公开（公告）日：2006-01-26

  Quinazolines of the formula (I) in which R, R 1 , R 2 , R 3 , R 4 and Y have the meaning indicated in Patent claim 1, and their salts or solvates as glycoprotein IbIX antagonists.

  公式（I）中的喹唑啉，其中R，R1，R2，R3，R4和Y具有专利权要求1中指示的含义，以其盐或溶剂合物作为糖蛋白IbIX拮抗剂。
• Amide compounds having MCH-antagonistic activity and medicaments comprising these compounds
  申请人：Boehringer Ingelheim Pharma GmbH & Co. KG

  公开号：US20040152742A1

  公开（公告）日：2004-08-05

  The present invention relates to amide compounds of general formula I 1 wherein the groups and residues A, B, b, W, X, Y, Z, R 1 , R 2 and R 3 have the meanings given in claim 1. Moreover the invention relates to pharmaceutical compositions containing at least one amide according to the invention. In view of the MCH receptor-antagonistic activity the pharmaceutical compositions according to the invention are suitable for the treatment of metabolic disorders and/or eating disorders, particularly obesity, bulimia, anorexia, hyperphagia and diabetes.

  本发明涉及一般式I1的酰胺化合物，其中基团和残基A、B、b、W、X、Y、Z、R1、R2和R3具有权利要求1中给出的含义。此外，本发明涉及至少含有本发明中一种酰胺的药物组合物。鉴于MCH受体拮抗活性，本发明中的药物组合物适用于治疗代谢性疾病和/或进食障碍，特别是肥胖症、暴食症、厌食症、过度进食和糖尿病。